Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI
Ryoho Ihara, MD, Kazushi Suzuki, MD, Atsushi Iwata, MD, Takeshi Iwatsubo, MD, the Japanese Alzheimer’s Disease Neuroimaging Initiative
1The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Neurology, The University of Tokyo, Tokyo, Japan, 3Department of Neuropathology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research
Jacobo Mintzer, MD, MBA, Mike Spline, Erin Behc, MPH
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA, 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of alzheimer’s biomarkers: β-amyloid 1-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform
Satya Nandana Narla, Amanda Dider, Ming Hu, Tina LV, Yuan Xueling and Martine Florent
1Immunology Department, Covance Central Laboratories, Indianapolis, USA, 2Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Alessandro Trebbastoni, MD, PhD, Marco Canevelli, MD, PhD, Giuseppe Bruno, MD, Carlo de Lena, MD, Letizia Imbriano, Fabrizia D’Antonio, MD, Laura Pieron
1Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance
Jacobo Mintzer, MD, MBA, Mike Spline, Erin Behc, MPH
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA, 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais
Catherine Adnet-Bonte, MD, Brigitte Leprince, Laetitia Breuil, PhD, Florence Pasquier, MD, PhD
1Meotis, Centre Hospitalier Universitaire de Lille, France, 2Neurology Department, Centre Hospitalier Universitaire de Lille, France, 3Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer’s presentation
Jaime Perales, PhD, MPH, W Todd Moore, MS, Mariana Ramirez, LMSW, Linda Lara, BA, Erica Davis, BA, Jason Resendez, MS, Eric D Vidoni, PhD
1University of Kansas Medical Center, Kansas-USA, 2Guadalupe Center, Kansas City-USA, 3Don Bosco Senior Center, Kansas City-USA, 4LatinosAgainstAlzheimer’s Coalition, Chevy Chase-USA, 5Brain Research Center, Amsterdam, NL

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer’s disease (AD)
John Alam, Kelly Blatchburn, Niels Prins, Philip Scheltens
1EIP Pharma Inc., Cambridge, MA, USA, 2Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, 3Brain Research Center, Amsterdam, NL

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP, Michael Kornhauser BPharm, Ella Modini BSc, Harald Hampel, MD PhD, Stephan Toutain MS, Christopher Missling PhD
1HammondCare Dementia Centre, NSW, Australia, 2Sorbonne University, Paris, France, 3Anovex Life Sciences Corp, New York, USA

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study
Marielle Cajal-Berman, PhD, Jessica Branning, Vishnuharthi Nitta, MS
1Bioniclina Research, Orlando, FL, USA, 2ClinCloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials
Alberto Benussi, MD, Antonella Alberici, MD, Clarissa Ferrari, MD, Valentina Cantoni, MD, Valentina Dell’Era, MD, Rosanna Turrone, MS, Maria Sofia Cotelli, MD, Giuliano Binetti, MD, Barbara Paghera, MD, Giacomo Koch, MD, Barbara Borroni, MD, Alessandro Padovani, MD, PhD
*These authors contributed equally to this work.
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 2IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 3Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, 4Neurology Unit, Ospedale Vallecamonica, Esine, Brescia, Italy, 5Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy, 6Non Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Rome, Italy, 7Stroke Unit, Policlinico Tor Vergata, Rome, Italy


**P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trials**

Kenneth Stanley, Carolina Rubel, Lynne Hughes

IQVIA Project Leadership Unit

**P95 - CSF biomarkers outcomes in the ETHERAL AD study**

Harald Hampe, Carlos Buesa, Tamara Maes, Mabel Arevalo, Michele Lufino, Roger Bullock

Axa Research Fund & Sorbonne University Chair, Paris, France; Sorbonne University, QRC, n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitie-Salpetriere Hospital, Paris, France; Brain & Spine Institute (ICM), INSERM U1077, CNRS UMR 7225 Paris, France; Institute of Memory and Alzheimer’s Disease (IMADA), Department of Neurology, Pitie-Salpetriere Hospital, AP-HP, Paris, France; Oryzon Genomics SA, Barcelona, Spain

**P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer’s Disease**

Preciosa M Coloma, Stephanie J. B. Vos, Isabelle Bos, Andy Simmons, Rih Vandenberghe, Philip Scheltens, José Luis Molinuevo, Flavio Nobili, Sebastiaan Engelborghs, Giovanni Frisoni, Gaël Chetelat, Alberto Lleó, Anders Wallin, Julius Popp, Pablo Martínez-Lage, Gonzalo Durán-Pacheco, Pieter Jelle Visser, Mark F Gordon, Gerald Novak

Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland; Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands; Institute of Psychiatry, Kings College, London, UK; University Hospital Leuven, Leuven, Belgium; Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; Alzheimer’s disease & other cognitive disorders unit, Hospital Clinic-IDIBAPS, Barcelona, Spain; Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain; Clinical Neurology, Department of Neurosciences (DINOCM), University of Genoa and IRCSS Polyclinic San Martino Hospital, Genoa, Italy; Department of Neurology and Memory Clinic, Hospital Netwook Antwerp (ZNA) Middelem and Hage Beuken, Antwerp, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Bom-Bunge, University of Antwerp, Antwerp, Belgium; University of Geneva, Geneva, Switzerland; IRCSS Istituto Centro San Giovanni di Dio Fasettabeneiarei, Brescia, Italy; Inserm, INSERM UMR-S U1237, Université de Caen-Normandie, GIP Cyclon, Caen, France; Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden; Geriatric Psychiatry, Department of Mental Health and Psychology, Geneva University Hospitals, Switzerland; Department of Psychiatry, Universitat Hospital de Lausanne, Lausanne, Switzerland; CITA-Alzheimer Foundation, San Sebastian, Spain; Teva Pharmaceuticals, Malvern, PA, USA; Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

**P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders**

Roger Bullock, David Rottlant, Michele Lufino, Cristina Mascaro, Carlos Buesa, Tamara Maes, Sonia Gutierrez, Marta Valverde, Tony Ramos

Oryzon Genomics, Barcelona, Spain; Vall D’Hebron Hospital, Barcelona, Spain

**P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer’s disease trials?**

Piers Kotting, MBA, Kris Beicher, Adam Smith, Clare Shaw, PhD

University of Exeter Medical School, Exeter, UK; University of Leeds, Leeds, UK; Institute of Neuroscience, University College London, London, UK

**P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease**

Smiljana Ristic, MD, Mercé Boada, MD, PhD, Nathalie Pross, PhD, Danielle Abi-Saab, Psyd, Szofia Bullain, MD, Mirjana Andjelkovic, PhD, Paul Delmar, PhD, Carsten Hofmann, PhD, Alison Searle, BSc, Monika Baudler, PhD, Smiljana Ristic, MD, PhD

F. Hoffmann-La Roche Ltd., Basel, Switzerland; Barcelona Alzheimer Treatment and Research Center, Barcelona, Spain; Roche Products Ltd, Welwyn Garden City, UK; Genentech, Inc., South San Francisco, CA, USA

**P100 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trials**

CTAD 2018

**P101 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes**

Richard E. Kennedy, MD, PhD, Guoqiao Wang, PhD, Mackenzie E. Fowler, MPH, Gary R. Cutter, PhD, Lon S. Schneider, MD, MS

Department of Medicine, University of Alabama at Birmingham, USA; Division of Biostatistics, Washington University, St. Louis, USA; Department of Epidemiology, University of Alabama at Birmingham, USA; Department of Biostatistics, University of Alabama at Birmingham, USA; Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA